celltrion
FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion
November 29, 2018Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion
The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …
Are biosimilars key to solving NHS access concerns?
October 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, Pfizer, UK, biosimilars, celltrion, pharma
In light of continued austerity gripping the NHS, it was uplifting to hear in July that the health service had …
Celltrion’s Herceptin biosimilar seals EU approval
February 15, 2018Sales and Marketing EU, Europe, Herceptin, Herzuma, celltrion, pharma
Herzuma, Celltrion’s biosimilar version of Roche/Genentech’s blockbuster immunotherapy Herceptin, has been awarded approval from the European Commission, the company has …
First biosimilar for European cancer treatment given approval
February 23, 2017Sales and Marketing biosimilar, celltrion
The first biosimilar will be made available in Europe to match the indications of Roche’s best-selling cancer drug, Rituxan. The …
FDA advisory committee recommends approval of Remicade biosimilar
February 10, 2016Research and Development, Sales and Marketing FDA, Pfizer, Remicade, biosimilar, celltrion
An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …
Data supports switching to Hospira biosimilar for RA
June 10, 2015Research and Development, Sales and Marketing EULAR, Hospira, Janssen, RA, brett wells, celltrion, inflectra, rome
Findings presented at EULAR this week from the first real-world study in patients with rheumatic diseases supports switching from J&J’s …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
